Leustatine (Cladribine)

Cladribine is a purine nucleoside analog that is converted inside cells to a triphosphate form. This active metabolite is incorporated into DNA during replication, causing breaks and preventing repair, which leads to programmed cell death of proliferating lymphocytes, especially malignant B‑cells.

The specific dose and schedule of Leustatine are determined by the prescribing physician based on the patient’s diagnosis, disease stage, and individual health factors. Dosing regimens are tailored to achieve therapeutic effect while minimizing risk, and should not be altered without medical guidance.

Safety data for cladribine in pregnancy and lactation are limited. It is generally advised to avoid use in pregnant or nursing women unless the potential benefit justifies the potential risk to the fetus or infant. Physicians should discuss alternative options and risk mitigation strategies.

To request Leustatine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Leustatine (cladribine) belongs to the antimetabolite class, offering a targeted mechanism of lymphocyte depletion. Compared with conventional chemotherapy, it often requires fewer treatment cycles and may have a different side‑effect profile. In multiple sclerosis, it provides an oral‑like dosing schedule versus injectable disease‑modifying therapies, but choice depends on individual patient factors.

Leustatine must be stored refrigerated between 2 °C and 8 °C. The product should be kept in its original packaging, protected from light, and must not be frozen or shaken. Proper cold‑chain handling during transport is essential to maintain stability and efficacy.

Leustatine is supplied as an intravenous solution that is administered by a qualified healthcare professional. The infusion is given through a vein over a prescribed period, typically in a clinical setting such as a hospital or infusion centre, following the dosing schedule set by the treating physician.

The most serious risks include severe lymphopenia leading to opportunistic infections, rare cases of secondary malignancies, autoimmune hepatitis, and life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, liver dysfunction, and dermatologic changes throughout therapy.

Leustatine is contraindicated in patients with active severe infections, known hypersensitivity to cladribine or any excipients, and those who are pregnant unless the benefit outweighs the risk. Caution is also advised for individuals with significant renal impairment or uncontrolled autoimmune disorders, and the decision should be made by a qualified physician.